{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:56:16Z","timestamp":1777625776047,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.1093\/jac\/dkx150","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T19:09:54Z","timestamp":1493838594000},"page":"2326-2333","source":"Crossref","is-referenced-by-count":32,"title":["Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?"],"prefix":"10.1093","volume":"72","author":[{"given":"Thomas","family":"Maitre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Petitjean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Chauffour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najoua","family":"El Helali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Reibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Chavanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"key\n\t\t\t\t20171012130357_dkx150-B1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1993.03510010071032","article-title":"Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance","volume":"270","year":"1993","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B2","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B3","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1001\/jama.300.18.2153","article-title":"Extensively drug-resistant tuberculosis in the United States, 1993-2007","volume":"300","year":"2008","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijid.2015.09.002","article-title":"Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register","volume":"39","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1164\/rccm.200911-1656OC","article-title":"Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis","volume":"182","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B6","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1128\/AAC.00968-10","article-title":"Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B7","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1128\/AAC.00506-13","article-title":"Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B8","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B9","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.201303-0604OC","article-title":"Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis","volume":"188","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B11","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkr566","article-title":"A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B13","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1093\/jac\/dkw344","article-title":"In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests","volume":"71","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mcp.2000.111482","article-title":"Effect of a single oral dose of moxifloxacin (400\u2009mg and 800\u2009mg) on ventricular repolarization in healthy subjects","volume":"68","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2007.10.021","article-title":"Pharmacokinetics\/pharmacodynamics of levofloxacin 750mg once daily in young women with acute uncomplicated pyelonephritis","volume":"31","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B18","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1128\/AAC.43.9.2323","article-title":"Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients","volume":"43","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B20","article-title":"Measurement of antibiotics in human body fluids","volume-title":"Antibiogram"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy","volume":"51","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B22","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.00135-13","article-title":"Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B24","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1128\/AAC.00425-16","article-title":"Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug-resistant tuberculosis","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.201510-2091OC","article-title":"Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value","volume":"194","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B26","volume-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis","year":"2014"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jac\/dkv360","article-title":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB","volume":"71","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B28","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/AAC.04058-14","article-title":"Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1099\/jmm.0.046821-0","article-title":"Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin","volume":"62","year":"2013","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0924-8579(00)00337-X","article-title":"In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis","volume":"17","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijantimicag.2008.04.025","article-title":"Urinary bactericidal activity of single doses (250, 500, 750 and 1000mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli","volume":"32","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B34","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","article-title":"Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B35","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1073\/pnas.1525047113","article-title":"Crystal structure and stability of gyrase\u2013fluoroquinolone cleaved complexes from Mycobacterium tuberculosis","volume":"113","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1164\/rccm.201212-2328OC","article-title":"Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis","volume":"188","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B37","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1128\/AAC.47.10.3117-3122.2003","article-title":"Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo","volume":"47","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B38","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.47.3.833-836.2003","article-title":"Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary","volume":"47","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00044011-200525100-00003","article-title":"In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils","volume":"25","year":"2005","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1128\/AAC.49.6.2429-2437.2005","article-title":"Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages","volume":"49","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012130357_dkx150-B42","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1021\/cb500629k","article-title":"Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design","volume":"9","year":"2014","journal-title":"ACS Chem Biol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/8\/2326\/18801437\/dkx150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T05:03:28Z","timestamp":1569215008000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/72\/8\/2326\/3849381\/Are-moxifloxacin-and-levofloxacin-equally"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,5,23]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx150","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,5,23]]}}}